Delivery Order SPE2DB22D2206-SPE2DB25FJS92
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $6,165.34 to AmerisourceBergen Drug Corp for BENLYSTA 200 mg/ml auto-injectors, with an ultimate completion date of September 23, 2025. This competitively awarded, firm fixed-price delivery order was issued under no set-aside restrictions. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran...
- The Defense Logistics Agency awarded a delivery order valued at $3,082.67 to AmerisourceBergen Drug Corp for Benlysta 200 mg/mL auto-injector units, with an ultimate completion date of September 8, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and is being performed at the contractor's corporate headquarters location in Conshohocken, Pennsylvania. The award is issued as a child contract under AmerisourceBergen Drug Corp's existing...
- The Defense Logistics Agency awarded a $9,248.01 delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/mL auto-injectors, with a completion date of September 24, 2025. This delivery order is priced on a firm fixed-price basis and was awarded competitively with no set-aside designation. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order valued at $12,330.68 to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector units. The contract, issued on September 2, 2025, with an ultimate completion date of September 23, 2025, represents a firm fixed-price procurement executed without set-aside provisions, indicating open competition. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, fulfills this order as part of its extensive federal...
- The Defense Logistics Agency awarded a $6,165.34 delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injectors, with performance in Conshohocken, Pennsylvania and a completion date of September 23, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The IDC, valued at $999,999,999.00 and extending through December 2026,...
- The Defense Logistics Agency awarded a delivery order valued at $12,330.68 to AmerisourceBergen Drug Corp for Benlysta 200 mg/mL auto-injector pharmaceutical product. This competitively awarded, firm fixed-price contract is scheduled for completion by September 15, 2025, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. The award represents a child order under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a delivery order valued at $18,496.02 to AmerisourceBergen Drug Corp for Benlysta 200 mg/mL auto-injectors. The contract, awarded on August 28, 2025, with an ultimate completion date of September 19, 2025, utilizes firm fixed-price pricing and represents a non-competitive set-aside. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor and healthcare solutions provider for federal medical...
- The Defense Logistics Agency awarded a delivery order valued at $9,248.01 to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector on August 28, 2025, with completion expected by September 19, 2025. This firm fixed-price delivery order is unclassified as a set-aside contract and represents a competitive award to the pharmaceutical distributor. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Benlysta 200 mg/mL auto-injector, valued at $6,165.34. This is a firm fixed price, non-competitive delivery order with an ultimate completion date of September 12, 2025. The order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Benlysta 200 mg/ml auto-injector pharmaceutical products under a firm fixed-price contract with a ceiling value of $6,165.34. The delivery order, issued on September 3, 2025, is scheduled for completion by September 24, 2025, and represents a non-competitive procurement action. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJS92Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,082.67 to AmerisourceBergen Drug Corp for Benlysta 200 mg/mL auto-injectors, with an ultimate completion date of September 23, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly serving military and veteran healthcare systems through the DLA's Medical Supply Chain. This delivery order represents a small-value transaction under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. That prime contract vehicle enables the company to supply a comprehensive range of pharmaceutical products and medical supplies globally to support military healthcare programs, including the Defense Health Agency and U.S. Coast Guard. The current award for Benlysta, a specialty biologic medication used in rheumatologic treatment, exemplifies the company's role in delivering specialized pharmaceutical commodities across multiple therapeutic domains to federal customers.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.1k | 9/2/25 |